salicylsalicylic acid has been researched along with Albuminuria in 2 studies
salicylsalicylic acid: structure
salsalate : A dimeric benzoate ester obtained by intermolecular condensation between the carboxy of one molecule of salicylic acid with the phenol group of a second. It is a prodrug for salycylic acid that is used for treatment of rheumatoid arthritis and osteoarthritis and also shows activity against type II diabetes.
Albuminuria: The presence of albumin in the urine, an indicator of KIDNEY DISEASES.
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Goldfine, AB | 1 |
Fonseca, V | 1 |
Jablonski, KA | 1 |
Pyle, L | 1 |
Staten, MA | 1 |
Shoelson, SE | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Targeting Inflammation to Treat Cardiovascular Aging in Humans (TIVA Study)[NCT01775865] | Phase 2 | 59 participants (Actual) | Interventional | 2012-09-30 | Completed | ||
Targeting Inflammation Using Salsalate in CardioVascular Disease (TINSAL-CVD)[NCT00624923] | Phase 2/Phase 3 | 340 participants (Actual) | Interventional | 2008-09-30 | Completed | ||
Targeting Inflammation in Type 2 Diabetes: Clinical Trial Using Salsalate[NCT00799643] | Phase 2/Phase 3 | 638 participants (Actual) | Interventional | 2008-11-30 | Completed | ||
Targeting Inflammation in Type 2 Diabetes: Clinical Trial Using Salsalate[NCT00392678] | Phase 2/Phase 3 | 277 participants (Actual) | Interventional | 2006-10-31 | Completed | ||
Using Salsalate to Target Adipocyte Macrophage Infiltration and Reverse Metabolic Disease Risk in Obese Hispanic Young Adults[NCT02130804] | Phase 1 | 30 participants (Actual) | Interventional | 2011-07-31 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Endothelial function (NCT01775865)
Timeframe: Change from baseline brachial artery FMD at 4 weeks
Intervention | Percent dilation (Mean) | |
---|---|---|
Baseline | 4 Weeks | |
Placebo | 3.57 | 2.50 |
Salsalate | 3.49 | 4.60 |
Young Control Group | 5.88 | NA |
Aortic stiffness (NCT01775865)
Timeframe: Change in CFPWV from baseline at 4 weeks
Intervention | cm/sec (Mean) | |
---|---|---|
Baseline | 4 weeks | |
Placebo | 785.1 | 740.01 |
Salsalate | 831.3 | 839.6 |
Young Control Group | 538.0 | NA |
secondary (NCT00624923)
Timeframe: Baseline to 30 mo
Intervention | mg/dL (Mean) |
---|---|
1- Active Pharmacologic | 5.1 |
2- Placebo | 2.0 |
Secondary outcome, change in liver inflammation associated with NASH: ALT (NCT00624923)
Timeframe: baseline to 30 mo
Intervention | U/L (Mean) |
---|---|
1- Active Pharmacologic | -1.1 |
2- Placebo | -0.6 |
Secondary outcome of change in inflammation marker CRP (NCT00624923)
Timeframe: baseline to 30 mo
Intervention | mg/L (Mean) |
---|---|
1- Active Pharmacologic | -0.1 |
2- Placebo | -0.1 |
(NCT00624923)
Timeframe: Baseline to 30 months
Intervention | mm^3 (Mean) |
---|---|
1- Active Pharmacologic | 0 |
2-Placebo | 0 |
(NCT00799643)
Timeframe: 48 weeks from baseline
Intervention | mg/dl (Mean) |
---|---|
Placebo | 2.0 |
Salsalate | -13.1 |
HbA1c (%, percentage of HbA1c) change from baseline. (NCT00799643)
Timeframe: 48 weeks from baseline
Intervention | HbA1c units are % (Mean) |
---|---|
Placebo | -0.04 |
Salsalate | -0.33 |
(NCT00392678)
Timeframe: 14 week
Intervention | mg/dl (Mean) |
---|---|
Placebo | 13 |
Salsalate 3.0 g/d | -19 |
Salsalate 3.5 g/d | -14 |
Salsalate 4.0 g/d | -15 |
HOMA-IR was not calcuated due to potential confounding effect of salicylates to inhibit insulin clearance. Change in insulin from Baseline to Week 14 in data table below. (NCT00392678)
Timeframe: Baseline, week 14
Intervention | pmol/l (Median) |
---|---|
Placebo | -3.0 |
Salsalate 3.0 g/d | 15 |
Salsalate 3.5 g/d | 7.6 |
Salsalate 4.0 g/d | 27 |
Change from baseline to either 14 or 26 weeks, or last HbA1c measurement prior to rescue therapy (NCT00392678)
Timeframe: 14 week
Intervention | % HbA1c (Mean) |
---|---|
Placebo | 0 |
Salsalate 3.0 g/d | -0.4 |
Salsalate 3.5 g/d | -0.3 |
Salsalate 4.0 g/d | -0.5 |
The primary outcome for the TINSAL-T2D study is change in HbA1c level from baseline to week 14 (stage 1) in the intent-to-treat (ITT) population with last observation carried forward. (NCT00392678)
Timeframe: 14 week
Intervention | % (units of HbA1c) (Mean) |
---|---|
3.0 g/d | -0.36 |
3.5 g/d | -0.34 |
4.0 g/d | -0.49 |
Placebo | -0.01 |
HOMA-IR was not calcuated due to potential confounding effect of salicylates to inhibit insulin clearance. Change in C-peptide from Baseline to Week 14 is in the data table below (NCT00392678)
Timeframe: Baseline, week 14
Intervention | C-peptide in nmol/l (Mean) |
---|---|
Placebo | 0.10 |
Salsalate 3.0 g/d | -0.07 |
Salsalate 3.5 g/d | -0.03 |
Salsalate 4.0 g/d | 0.03 |
See adverse event module for details. Safety and tolerability of salsalate compared to placebo as assessed by adverse events. (NCT00392678)
Timeframe: 14 weeks
Intervention | participants (Number) |
---|---|
Salsalate 3.0 g/d | 17 |
Salsalate 3.5 g/d | 16 |
Salsalate 4.0 g/d | 16 |
Placebo | 14 |
"Change in lipids (low-density lipoprotein cholesterol [LDL-C], non-high-density lipoprotein cholesterol [non-HDL-C], triglycerides [TG], total cholesterol [TC], high-density lipoprotein cholesterol [HDL C], TC/HDL-C ratio, and LDL-C/HDL-C ratio)~LDL-C/HDL-C ratio not calculated" (NCT00392678)
Timeframe: 14 week
Intervention | mg/dl (Mean) | ||||
---|---|---|---|---|---|
Cholesterol | HDL | LDL | TG | Total to HDL ratio | |
Placebo | 0 | 0 | 0 | 15 | 0 |
Salsalate 3.0 g/d | 8 | 3 | 15 | -34 | 0.1 |
Salsalate 3.5 g/d | -1 | 1 | 3 | -22 | -0.1 |
Salsalate 4.0 g/d | 6 | 2 | 8 | -16 | 0.2 |
1 trial available for salicylsalicylic acid and Albuminuria
Article | Year |
---|---|
The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial.
Topics: Adolescent; Adult; Aged; Albuminuria; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; | 2010 |
The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial.
Topics: Adolescent; Adult; Aged; Albuminuria; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; | 2010 |
The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial.
Topics: Adolescent; Adult; Aged; Albuminuria; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; | 2010 |
The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial.
Topics: Adolescent; Adult; Aged; Albuminuria; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; | 2010 |
The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial.
Topics: Adolescent; Adult; Aged; Albuminuria; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; | 2010 |
The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial.
Topics: Adolescent; Adult; Aged; Albuminuria; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; | 2010 |
The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial.
Topics: Adolescent; Adult; Aged; Albuminuria; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; | 2010 |
The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial.
Topics: Adolescent; Adult; Aged; Albuminuria; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; | 2010 |
The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial.
Topics: Adolescent; Adult; Aged; Albuminuria; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; | 2010 |
The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial.
Topics: Adolescent; Adult; Aged; Albuminuria; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; | 2010 |
The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial.
Topics: Adolescent; Adult; Aged; Albuminuria; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; | 2010 |
The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial.
Topics: Adolescent; Adult; Aged; Albuminuria; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; | 2010 |
The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial.
Topics: Adolescent; Adult; Aged; Albuminuria; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; | 2010 |
The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial.
Topics: Adolescent; Adult; Aged; Albuminuria; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; | 2010 |
The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial.
Topics: Adolescent; Adult; Aged; Albuminuria; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; | 2010 |
The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial.
Topics: Adolescent; Adult; Aged; Albuminuria; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; | 2010 |
The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial.
Topics: Adolescent; Adult; Aged; Albuminuria; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; | 2010 |
The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial.
Topics: Adolescent; Adult; Aged; Albuminuria; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; | 2010 |
The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial.
Topics: Adolescent; Adult; Aged; Albuminuria; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; | 2010 |
The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial.
Topics: Adolescent; Adult; Aged; Albuminuria; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; | 2010 |
The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial.
Topics: Adolescent; Adult; Aged; Albuminuria; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; | 2010 |
The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial.
Topics: Adolescent; Adult; Aged; Albuminuria; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; | 2010 |
The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial.
Topics: Adolescent; Adult; Aged; Albuminuria; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; | 2010 |
The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial.
Topics: Adolescent; Adult; Aged; Albuminuria; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; | 2010 |
The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial.
Topics: Adolescent; Adult; Aged; Albuminuria; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; | 2010 |
1 other study available for salicylsalicylic acid and Albuminuria
Article | Year |
---|---|
Summaries for patients. The effects of salsalate on blood sugar control in people with type 2 diabetes.
Topics: Adolescent; Adult; Aged; Albuminuria; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; | 2010 |